Miguel Regueiro, MD

Cleveland Clinic Lerner College of Medicine, Case Western Reserve University

Poster(s):

• P2210 - Mirikizumab Sustained Improvement on Fatigue in Patients with Moderately to Severely Active Crohn’s Disease in the Phase 2 AMAG Study at Week 104
  Monday, October 23, 2023

  10:30 AM – 4:15 PM PT

• P2211 - Hepatic Impact of Etrasimod for Treatment of Moderately to Severely Active Ulcerative Colitis: An Integrated Safety Summary From the Etrasimod Ulcerative Colitis Clinical Program
  Monday, October 23, 2023

  10:30 AM – 4:15 PM PT